Characteristics of incidental hepatocellular carcinomas and of contemporaneous non- randomised controls
| Incidental hepatocellular carcinomas | Control group | p Value | |
|---|---|---|---|
| No of patients | 61 | 104 | |
| Sex (M/F) | 43/18 | 70/34 | |
| Age (y)4-a | 61.8 (10.3) | 63.8 (11.1) | |
| Child-Pugh class | |||
| A | 25 | 40 | |
| B | 29 | 51 | |
| C | 7 | 13 | |
| Unifocal HCC at US | 49 (80%) | 55 (53%) | <0.001 |
| Diffuse/infiltrat. HCC at US | 6 (10%) | 30 (29%) | <0.01 |
| Volume of single HCCs4-a (cm3) | 12.5 (18.9) | 20.1 (42.2) | |
| Diameter of single HCCs4-a (cm) | 2.73 (1.08) | 3.34 (3.20) | |
| Eligibility for treatment | 42 (69%) | 61 (59%) | |
| Assigned treatment | |||
| TACE | 13 (31%) | 28 (46%) | <0.05 |
| PEI | 10 (24%) | 14 (23%) | |
| TACE+PEI | 4 (10%) | 6 (10%) | |
| Hepatic resection | 4 (9%) | 5 (8%) | |
| OLT | 11 (26%) | 8 (13%) | <0.01 |
| Median survival (months) | 30 | 15 | <0.02 |
↵4-a Data are expressed as mean (SD). Percentages are rounded to integers.
HCC, hepatocellular carcinoma; OLT, orthotopic liver transplantation; PEI, percutaneous ethanol injection; TACE, transarterial chemoembolisation; US, ultrasonography.